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Abstract 
The overall 5-year survival for melanoma is 91%. However, if distant metastasis occurs 
(stage IV), cure rates are < 15%. Hence, melanoma detection in earlier stages (stages I-III) 
maximises the chances of patient survival.  We measured the expression of a panel of 17 
microRNAs (miRNAs) (‘MELmiR-17’) in melanoma tissues (stage III; n=76 and IV; n=10) 
and serum samples (collected from controls with no melanoma, n=130; and patients with 
melanoma (stages I/II, n=86; III, n=50; and IV, n=119)) obtained from biobanks in Australia 
and Germany. In melanoma tissues, members of the ‘MELmiR-17’ panel were found to be 
predictors of stage, recurrence, and survival. Additionally, in a minimally-invasive blood test, 
a seven-miRNA panel (‘MELmiR-7’) detected the presence of melanoma (relative to 
controls) with high sensitivity (93%) and specificity (≥82%) when ≥4 miRNAs were 
expressed. Moreover, the ‘MELmiR-7’ panel characterised overall survival of melanoma 
patients better than both serum LDH and S100B (delta log likelihood = 11, p<0·001). This 
panel was found to be superior to currently used serological markers for melanoma 
progression, recurrence, and survival; and would be ideally suited to monitor tumour 
progression in patients diagnosed with early metastatic disease (stage IIIa-c/IV M1a-b) to 
detect relapse following surgical or adjuvant treatment. 
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Abbreviations 
AGO2, argonaute RISC catalytic component 2; AJCC, American Joint Committee on Cancer; 
AUC, area under the curve; AUROC, area under the receiver operator curve; CI, confidence 
interval; Ct, threshold cycle; DOR, diagnostic odds ratio; FFPE, Formalin-fixed paraffin-
embedded; HR, hazard ratio; LDH, lactate dehydrogenase; M1a, metastasis to skin, 
subcutaneous (below the skin) tissue, or lymph nodes in distant parts of the body, with a 
normal blood LDH level; M1b, metastasis to the lungs, with a normal blood LDH level; M1c, 
metastasis to any other organs, OR distant spread to any site along with an elevated blood 
LDH level; MIA, Melanoma Institute of Australia; miR, microRNA; miRNA, microRNA; N 
stage, nodal or number of lymph nodes stage; NA, not applicable; NM, nodular melanoma; 
OR, odds ratio; PD1, Programmed cell death protein; RNA, Ribonucleic acid; S100B, S100 
calcium-binding protein B; USA, United States of America; SMM, superficial spreading 
melanoma.  
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Highlights 
 A seven-miRNA panel (‘MELmiR-7’) detected the presence of melanoma with high 
sensitivity (93%) and specificity (≥82%).  
 In serially collected stage IV specimens, members of the ‘MELmir-7’ panel confirmed 
tumour progression in 100% of cases 
 The ‘MELmir-7’ panel is superior to currently used serological markers for melanoma 
progression, recurrence, and survival. 
Research in context 
The use of melanoma progression markers have been used for many years however it is clear 
from the survival rates (5-year survival of Stage IV patients is <15%) that melanoma must be 
detected before disease progresses thus highlighting that the current methods of progression 
detection are inadequate. We have identified a seven-miRNA panel (‘MELmiR-7’) that has 
the ability to detect the presence of melanoma with high sensitivity and specificity which is 
superior to currently used markers for melanoma progression, recurrence, and survival. This 
panel may enable more precise measurement of disease progression and may herald an 
increase in overall survival. 
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Introduction 
Melanomas are among the most commonly occurring cancers. Crude incidence rates in 
Australia
1
 and the USA
2
 were approximately 50 cases (in 2010) and  20 cases (in 2011) per 
100,000 respectively. With the number of new cases rising each year, melanoma is currently 
is listed as the 4th and 6th most common cancer in Australia and the USA respectively.
1, 
2
Current clinical staging criteria classify melanoma progression from a pre-invasive lesion, 
confined to the epidermis (stage 0), a series of early stages of local invasion (I and II), a stage 
involving regional lymph nodes (stage III) and finally metastasis to distant sites (stage IV). 
The overall 5-year survival for melanoma is 91%, which is largely due to curative surgery for 
early stage disease. However, cure rates are < 15%
3
 if distant metastasis occurs (stage IV; 
AJCC 7
th
 edition). We now have evidence that current therapeutic options for late stage 
disease are more effective if the disease treated with lower disease burden.
4, 5
 Hence, 
melanoma must be treated in earlier stages to maximise the chances of patient survival. 
Therefore, the ability to identify signs of melanoma progression sooner would be a valuable 
clinical tool. 
Melanoma progression biomarkers have been studied intensively with varying levels of 
success. Serum lactate dehydrogenase (LDH) levels have been integrated into current staging 
regimens
3
 and elevation of LDH levels increases in specificity as disease progresses (stage II 
(83%), III (87%), and IV (92%)). However the sensitivity of this marker is reduced during 
progression (stage II (95%), III (57%), and IV (79%)).
6-11
 S-100B, a calcium binding protein, 
is raised in serum of stage III and IV melanoma patients.
12, 13
 However, the proportion of 
patients with elevated S100B levels varies by stage: 0-9% in stage I/II, 5-98% in stage III, 
and 40-100% in stage IV (reviewed in
14
). As such, serum S100B is not routinely used in the 
clinic,
15
 highlighting the fact that the current serological methods of progression detection, 
whilst relatively specific, are inadequate due to variability in sensitivity across all stages of 
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disease. To date, there are no biomarkers that are sensitive or specific enough to be beneficial 
for early detection of melanoma (all stages). A blood test (‘circulating’ biomarkers) that 
detected melanoma with regional spread, prior to clinically evident distant metastasis, could 
improve treatment and outcomes for melanoma patients. 
For a circulating biomarker to be effective, not only must it be sufficiently sensitive and 
specific, but it must also be highly stable and resistant to degradation. In recent years, 
circulating microRNAs (miRNAs) have been studied for their utility as biomarkers in a wide 
range of malignancies and disorders.
16, 17
 miRNAs are small (20-22 nt) non-coding RNAs 
which function to regulate gene expression in the cell. Recently, tumour cells have been 
shown to release miRNAs into the circulation,
18
 contained primarily in micro-vesicles or 
exosomes (extracellular vesicles), or bound to AGO2 - a part of the miRNA-mediated 
silencing complex.
16, 17
 Due to the ‘encapsulation’ of these miRNAs in serum or plasma they 
are highly resistant to degradation by RNases (highly concentrated in the blood), thus their 
potential usefulness as a ‘biomarker’ is relatively high. To date, circulating melanoma-related 
miRNAs have been rarely studied.
19, 20
  
Herein we report a multi-centre study that identifies a panel of ‘melanoma-related’ miRNAs 
that offer superior sensitivity to currently used serological markers for melanoma 
progression, recurrence, and survival. 
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Materials and Methods 
Patient specimen details 
Formalin-fixed paraffin-embedded (FFPE) melanoma tissues and serum (melanoma and 
control patients) were obtained from prospectively collected biobanks in Australia and 
Germany. 
Tissue validation cohort 
FFPE melanoma tissues, collected at diagnosis of stage III (‘PAH-tissue’) were obtained via a 
database of prospective stage IIIA-C cutaneous melanoma cases, presenting to the Princess 
Alexandra Hospital (PAH) Melanoma Unit and affiliated private hospitals, which has been 
maintained since 1997. Permission to collect and use information was approved by the 
hospital ethics committee (HREC Reference number: HREC/11/QPAH/650; SSA reference 
number: SSA/11/QPAH/694). Inclusion criteria were the same as those previously 
presented.
21
 An additional collection (collected at diagnosis) of stage III and IV melanoma 
tissues (‘MIA-tissue’) were obtained via a database of prospectively recruited melanoma 
cases, presenting to the Melanoma Institute Australia and affiliated private hospitals, which 
has been maintained since 1967. Informed written consent was obtained for each patient 
under approved protocols (Protocol No X10-0305 &HREC/10/RPAH/539 and Protocol No 
X10-0300 HREC/10/RPAH/530) governed by the Human Research Ethics Committee of the 
Royal Prince Alfred Hospital (Sydney NSW, Australia). Inclusion criteria were the same as 
those previously presented.
21
 See Table 1 for participant descriptive statistics. Supplementary 
Table 2 shows the mean, median, and range of follow-up times. 
Serum validation cohorts: Control sera 
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Sera from ‘Healthy Controls’ were ascertained from a cohort of participants collected as part 
of the Australian Cancer Study (ACS) (QIMR Berghofer HREC approved project no. P399). 
As part of the ACS, potential controls were randomly selected from the Australian Electoral 
Roll (enrolment is compulsory). Controls were prospectively sampled from within strata of 
age (in 5 year age-groups) and state of residence.  Of 3,258 potentially eligible control 
participants, 41 could not be contacted and 175 were excluded because they were deceased 
(16), too ill (61), or unable to read or write in English (98). Of 3,042 controls meeting the 
inclusion criteria, 1680 (55%) gave their consent to take part. Completed questionnaires were 
returned by 1580 controls (48% of all potentially eligible controls selected from the roll). See 
Table 2 for participant descriptive statistics. 
Sera from ‘High naevus count’ and ‘History of melanoma, disease-free’ participants were 
prospectively collected from cohorts who were enrolled in the study: ‘Pigmentation 
genotypes and phenotypic correlations with dermoscopic naevus types and distribution’. 
These samples were included as ‘controls’ to determine the level of expression measurable in 
sera derived from patients with a high melanocyte burden. All study participants were 
enrolled in the following human ethics approved projects: QIMR HREC/P1237, The Metro 
South Health District HREC/09/QPAH/162, and UQ HREC approval number is 2009001590. 
Participants with a history of melanoma (clinically free of disease at time of blood draw) 
were recruited through the Melanoma Unit and Dermatology Department of the Princess 
Alexandra Hospital, Brisbane, Queensland, Australia, between May 2012 and November 
2012. Control participants, with no personal history of melanoma, were recruited from the 
Brisbane Twin Naevus Study between August 2012 and November 2012. All participants had 
16-panel full-body images and dermoscopic images of significant naevi recorded2. 
Significant naevi were defined as naevi greater than or equal to 5mm on all body sites except 
the scalp, buttocks, mucosal surfaces and genitals, and greater than or equal to 2mm on the 
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back of both males and females and on the legs of females. All significant naevi were 
classified by the predominant dermoscopic pattern (reticular, globular, or non-specific), 
colour, and profile (flat, raised, domed or papillomatous). See Table 2 for participant 
descriptive statistics. 
The description of ‘controls’ used in the analyses refers to a combined cohort of ‘Healthy 
Controls’, ‘High naevus count’, and ‘History of melanoma, disease-free’ participants. 
Serum validation cohorts: Melanoma patient sera 
Sera from stage I-IV melanoma patients (at time of blood draw and staged according to the 
current AJCC staging manual3) had blood drawn and serum stored as part of a large 
prospectively collected cohorts from the university department of dermatology in Tubingen, 
Germany (‘Tubingen’ cohort) and Melanoma Institute of Australia, Sydney (‘MIA’ cohort). 
Usage of the ‘Tubingen’ bio-bank with corresponding patient data was approved by the 
Ethics Committee, University of Tübingen (approvals 657/2012BO2). Serially-collected 
stage IV patients (‘MIA’ cohort only) had blood drawn at time of diagnosis or at lower 
disease burden and then at higher disease burden (determined by routine diagnostic tests). All 
samples from the ‘MIA’ cohort had informed written consent obtained from each patient 
under approved protocols (Protocol No X10-0305 &HREC/10/RPAH/539 and Protocol No 
X10-0300 HREC/10/RPAH/530) governed by the Human Research Ethics Committee of the 
Royal Prince Alfred Hospital (Sydney NSW, Australia). See Table 2 for participant 
descriptive statistics. Supplementary Table 2 shows the mean, median, and range of follow-
up times. 
All serum samples were collected in 10-mL BD serum tubes then centrifuged for 10 minutes 
at 1,500 x g. The supernatant serum was then aliquoted into 1.5  mL cryovials and stored at 
−80°C until further use. 
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Total RNA extraction from validation cohorts 
A sterile disposable biopsy punch (Kai Medical, Japan) was used to retrieve tumour content 
from blocks that had been scored and marked for content via H&E histological staining. The 
extraction of total RNA from FFPE tissue and serum was performed respectively using 
miRNeasy FFPE Kits (QIAGEN) as per manufacturer’s instructions or as previously 
described.
21
 
Selection criteria for ‘melanoma-related’ miRNAs 
In our previously published miRNA microarray data
22
 we found a total of 233/1898 miRNAs 
(‘Discovery’ set) (Figure 1) that were differentially expressed (DE; corrected p≤0.05 and ≥2 
fold) between the melanoma cell lines (n=55) and the ‘other’ solid cancers (n=34). We 
applied filtering criteria to the 233 DE miRNAs to identify which miRNAs would be suitable 
to measure in patient derived serum. The following strict criteria were used to filter the 
‘Discovery’ set: ≥15 fold higher expression in cutaneous melanoma vs. ‘other’ solid 
malignancies (n=14/14), or ≥2 fold higher expression in cutaneous melanoma vs ‘other’ solid 
malignancies with no detectable expression in melanocytes or melanoblasts (n=3/6).  In 
addition, miR-16, which is known to be highly expressed in blood, was assessed for its 
suitability as an endogenous control. The 18 miRNA panel (‘MELmiR-18’) comprising: miR-
211-5p, miR-514a-3p, miR-509-3p, miR-204-5p, miR-509-5p, miR-513b, miR-145-5p, miR-
146a-5p, miR-508-3p, miR-506-3p, miR-513c-5p, miR-4731-5p, miR-508-5p, miR-363-3p, 
miR-4487, miR-4469, miR-4706, and miR-16. This panel was carried forward for testing in 
independent cohorts of FFPE melanoma tumours and patient derived sera. 
Reverse transcription, pre-Amplification, Taqman assays and Fluidigm real-time PCR.  
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We performed a custom Taqman assay combined with a sensitive method of detection 
(Fluidigm, HD Biomark) as previously described.
21
 Briefly, a custom reverse transcription 
(RT) primer pool consisting of equal amounts of miRNA-specific RT primers contained 
within each TaqMan® Assay (Life Technologies, Carlsbad, USA; miR-211-5p (000514), 
miR-514a-3p (001147), miR-509-3p (002236), miR-204-5p (000508), miR-509-5p (002235), 
miR-513b (002757), miR-145-5p (002278), miR-146a-5p (000468), miR-508-3p (001052), 
miR-506-3p (001050), miR-513c-5p (002756), miR-4731-5p (464084_mat), miR-508-5p 
(002092), miR-363-3p (001271), miR-4487 (462492_mat), miR-4469 (465059_mat), miR-
4706 (464518_mat), and miR-16
#
 (000391) along with cel-miR-39 (000200; serum spiked-in 
control) and RNU-6 (001973; FFPE endogenous control)) plus an additional pool of the 
corresponding TaqMan® MicroRNA Assay (Pre-Amp Primer Pool) were used to pre-amplify 
the RT reaction). Each assay had a serial dilution of a positive control sample (known 
expression for all miRNAs in panel) that had a total input of 1, 3, 15, and 45 ng in the 
original cDNA reaction. 
# The miR-16 Taqman primer assay (00039) is specifically designed to bind to mature 
miRNA sequence of miR-16-5p which is derived from hsa-mir-16-1 and hsa-miR-16-2 stem-
loop sequences. The alias for miR-16-5p is miR-16 hence the reasoning for the shortened 
name.  
qRT-PCR analysis 
The expression of the ‘MELmiR-18’ panel (Figure 1) was assayed in each sample with at 
least 4 technical replicate Taqman assays to determine their expression. Real-time expression 
data was extracted and analyzed as previously described.
21
 
Statistical Methods 
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The marker level differences (e.g. univariate analysis of each miRNA in each cohort 
comparison represented in Table 3) were assessed using the Mann-Whitney U-test and 
adjusted for multiple comparisons using the Benjamini & Hochberg method. Significant 
markers' predictive ability was evaluated using receiver operating characteristic (ROC curve) 
and area under the curve (AUC) or AUROC. Univariate and multivariate logitistic 
regressions with backward covariate search based on AIC
23, 24
 were performed to identify 
significant markers which were associated with melanoma status/disease stages, when time to 
event information was missing. For survival and recurrence analyses, univariate and 
multivariate Cox proportional hazard model with backward covariate search based on AIC
23, 
24
 was performed. Time to follow-up was measured from date of blood collection which was 
≤1 month of staging. The proportional hazards assumption was also evaluated for each Cox 
regression.
25
 The model fits were compared using likelihood ratio test. The predictive 
abilities of the selected significant markers were evaluated using AUROC. The selected 
markers were then used to classify patients using conditional inference tree analysis.
26
 For 
serum markers, the cutoff point of each marker that characterized the melanoma status was 
determined to maximize AUROC statistics. 
5000 nonparametric bootstraps were performed, per cohort (e.g. controls versus stage IV) & 
microRNA analysis pairs, to obtain robust effect size estimates, p values (for univariate 
analysis) and AUROC. To reflect the uncertainties of the values greater than Ct 36, the values 
above 36 were replaced by random values from 37 to 40 during the bootstrap. The original 
data was analysed without this consideration and the final models were rerun using 5000 
bootstrap runs to generate robust outcomes. 
For the analyses, OptimalCutpoints (v1·1-3), boot, and party packages on R version 3·0·2 
were used to find cutpoints in univariate analyses (cohort vs. markers), boostrapping and tree 
analyses respectively. 
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ROC curves and scatter plots were drawn using Graph Pad Prism 6. Survival analysis was 
performed using R version 3·0·2. 
Diagnostic inclusion criteria, score assignment, and test evaluation 
To maximize the chances of having a positive signal in the patients serum, a combined stage 
IV cohort (n=119; ‘TUBINGEN’ and ‘MIA’) was compared with disease-free ‘controls’ 
(n=130; no history of melanoma or nevi, prior history of melanoma but disease-free, high 
nevus count with no melanoma). Initially, all members of the ‘MELmiR-17’ (miR-4469 was 
excluded due to assay failure) panel underwent a simple Mann–Whitney U test to identify the 
highly significant (p.<0·0001) miRNAs to be included in the next step (Figure 1). Those 
miRNAs that met these criteria then underwent AUROC analysis to determine their Area 
under the Curve (AUC) (Figures 1 and 2). AUC scores ≥0·70 were deemed to be 
diagnostically useful.
27
 The miRNAs that had an AUC ≥0·70  were interrogated further to 
classify the median-normalized Ct values as ‘high’ or ‘low’ expression (interpretation of the 
median normalized Ct expression values used to determine ROC curves were evaluated with 
the Optimal Cutoff algorithm (‘OptimalCutpoints’ R package v1.1-3). For those miRNAs that 
met the criteria for inclusion in the diagnostic panel (Figures 1 and 2), the patient was given a 
diagnostic score (ranging from 0-7) determined by the number of miRNAs that were present 
as ‘high’ and ‘low’ or ‘normal’ (most like the ‘control’ cohort). To be deemed positive for 
melanoma, the patients sample must have had a score ≥4 (max 7). A negative test was a score 
of 0-3. 
The following formulas were used to determine diagnostic test ability: Positive Predictive 
Value (PPV) or Precision = True Positive (TP)/(TP + False Positive (FP)); Negative 
Predictive Value (NPV) = True Negative (TN)/(False Negative (FN) + TN); Sensitivity = 
TP/(TP + FN); Specificity = TN/(FP + TN) False Positive Rate = 1 – Specificity; False 
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Negative Rate = 1 – Sensitivity; Likelihood Ratio Positive = Sensitivity/1-Specificity; 
Likelihood Ratio Negative = 1-Sensitivity/Specificity; Diagnostic Odds Ratio (DOR) = 
(TP/FN)/(FP/TN). 
Funding 
This project was funded by the National Health and Medical Research Council (NHMRC) of 
Australia. 
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Results 
Members of the ‘MELmiR-17’ panel are predictors of stage, recurrence, and survival in 
patient tissue. 
To confirm that miRNA expression was detectable in melanoma tissues prior to the serum 
assessment, we first measured an 18-miRNA panel (‘MELmiR-18’) in a prospective 
collection (Tissue validation cohort, see Materials and Methods) of melanoma tissues derived 
from stage III (n=76) and stage IV (n=10) melanoma patients (Table 1 and Figure 1). 
Expression was detected in all dilutions of a positive control (except miR-4469 which had 
assay failure thus the panel herein will be referred to as ‘MELmiR-17’) and in tissue samples 
(Figure 1), which indicated that even at low input levels, the assay and detection method was 
adequate (data not shown). We observed that thirteen miRNAs were differentially expressed 
when stage III tissues were compared with stage IV tissues (logistic regression, p<0·05; 
Supplementary Table 1 and Supplementary Figure 1). All but one of these miRNAs (miR-
204) showed higher levels in stage III compared with stage IV tissues (Supplementary Table 
1 and Supplementary Figure 1). Of these miRNAs, seven (miR-506-3p, miR-508-3p, miR-
508-5p, miR-509-3p, miR-509-5p, miR-513c, and miR-514a) were members of the miR-506-
514a cluster.
28
 Supplementary Table 1 summarises the associated AUROC analyses. 
Members of the miR-506-514 cluster, had AUC scores ranging from (0·65-0·79) with the 
highest scores being shared by miR-506-3p and miR-509-5p. To determine the minimum 
number of miRNAs required to discriminate stage III from stage IV, we next performed a 
multivariate logistic regression and illustrated this using a conditional inference tree 
(Supplementary Figure 2). These analyses revealed that only miR-4731 (p=0·003, OR=3·0, 
CI 1·45-6·2) and miR-204 (p=0·015, OR=0·63, CI 0·43-0·92) were required to discriminate 
the tissue stage (in general, higher Ct values = lower expression). Subsequent AUROC 
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analysis (AUC=0·89) showed an improved score than individual miRNAs (Supplementary 
Table 1). 
We next used multivariate Cox regression modeling using the ‘MELmiR-17’ panel together 
with available records of pathology of the primary melanoma (SMM, NM) and number of 
involved nodes (N stage) to determine its value as a prognostic marker at stage III in the PAH 
tissue cohort (Table 1). These analyses showed that only nodular histotype (NM; p=0·002; 
HR=3·5; CI 1·57-7·81) and expression of miR-509-5p (p=0·015; HR=0·85; CI 0·75-0·97) 
were associated with overall survival. Expression levels of the ‘MELmiR-17’panel was not 
significantly different between the two largest pathology classes (SMM and NM) (data not 
shown). Furthermore, using the same multivariate analysis, N-stage (p=0·014; HR=1·52; CI 
1·09-2·12) and lower expression of miR-513b (p=0·038; HR=1·08; CI 1·00-1·17) and higher 
miR-513c expression (p=0·020; HR=0·92; CI 0·86-0·99) were related to recurrence. 
A seven-miRNA panel identifies melanoma with high sensitivity and specificity using patient 
sera. 
The ‘MELmiR-17’ panel was next assessed in independent cohorts of patient sera (Serum 
validation cohorts, see Materials and Methods) with different stages of disease at time of 
blood collection (from no melanoma to stages I-IV) (Table 2 and Figure 1). All expression 
values (Ct) were normalized to cel-miR-39 (synthetic ‘spike-in’ control) according to 
previously published methods
21
 prior to statistical analysis. In miRNA derived from serum, 
expression of 13 miRNAs was detected (Figure 1 and Table 3). Notably, the expression of the 
miR-506-514a cluster was generally quite low (miR-506-3p and miR-514a) or not detected 
(miR-508-3p, miR-508-5p, miR-513b, and miR-513c (data not shown)). In the 13 detected 
miRNAs, seven (miR-16, miR-211-5p, miR-4487, miR-4706, miR-4731, miR-509-3p, and 
miR-509-5p) showed highly significant differences (Mann-Whitney; corrected p<0·0001) 
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between ‘controls’ (no melanoma) and patients with stage IV disease (Table 3 and 
Supplementary Figures 3 and 4). The same miRNAs were also differentially detectable in 
stages I/II and stage III, compared with ‘controls’, with the exception of miR-211 (Table 3 
and Supplementary Figures 3 and 4). While miR-16 was originally included as a blood 
control, our data show that it is significantly associated with disease in both tissue and serum, 
as observed previously in a study of colorectal cancer.
29
 Intriguingly, levels of expression of 
most of these differentially expressed miRNAs were lower in melanoma patients compared to 
patients without disease (controls). The miRNAs -4487, -4706, -4731, 509-3p, and 509-5p all 
showed lower expression (on average) and miRNAs -16 and -211 (stage IV only) had higher 
expression (on average) in melanoma patients (Supplementary Figure 3). The observed lower 
serum expression of miR-4487, miR-4706, miR-4731, miR-509-3p, and miR-509-5p in the 
melanoma cases was associated with melanoma (presence of or recently removed tumour; see 
Discussion), and in the case of miR-509-3p, has been noted previously by Leidinger et al.
30
  
AUROC analysis revealed which of the differentially detected miRNAs (Table 3 and 
Supplementary Figure 5) have the potential to be used for diagnostic purposes. Particular 
attention is paid to those miRNAs that were able to discriminate stage IV disease (i.e. distal 
metastatic deposits) from disease-free controls (Table 3). These were: miR-16, miR-211-5p, 
miR-4487, miR-4706, miR-4731, miR-509-3p, and miR-509-5p (herein referred to as 
‘MELmiR-7’). Multivariate logistic regression identified the five most robust markers of the 
‘MELmiR-7’ panel (miR-211, p<0·0001; miR-509-3p, p=0·0014; miR-509-5p, p<0·0001; 
miR-4706, p=0·028; and miR-4731, p<0·0001). Subsequent AUROC analysis revealed these 
five markers produced a near perfect AUC score of 0·9907 (cf. ‘MELmiR-7’= 0·9911). 
Furthermore, a conditional inference tree analysis highlighted that patients could be 
discriminated into categories based on combinations of expression levels by members of the 
MELmiR-7 panel. Supplementary Figure 6 illustrates that only four miRNAs (miR-509-5p, 
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miR-miR-4731, miR-211, and miR-509-3p) were required to discriminate the stage IV 
samples (AUC=0·9738) from controls. Further comparisons showed that ‘MELmiR-7’ panel 
members can also discriminate stages I/II (AUC=0·991) and stage III (AUC=0·9722) from 
‘controls’ (Supplementary Figures 7 and 8). 
The sensitivity and specificity of the ‘MELmir-7’ was then assessed by assigning a diagnostic 
score to the data. The expression values graphed in the Supplementary Figure 3 were used to 
observe the direction of the data (i.e. higher or lower expression in ‘controls’ vs. all stages). 
The optimal cut points
24
 in the AUROC datasets were identified which allowed the 
expression values to be categorised as positive or negative for melanoma (see Materials and 
Methods). A diagnostic score (see Materials and Methods)) was then applied to each sample 
which ranged from 0 to 3 (low likelihood of melanoma) and 4 to 7 (high likelihood of 
melanoma). Upon applying the derived diagnostic score, the ‘MELmiR-7’ panel was 
evaluated as a group. We found that it had the ability to identify melanoma (independent of 
stage), when ≥4 miRNAs (93% sensitivity and ≥82% specificity) reached or exceeded their 
optimal cut point (Table 4). The sensitivity of the ‘MELmiR-7’ panel increased to 95% in the 
stage IV cohort. Table 4 provides a summary of the effectiveness of the ‘MELmiR-7’ panel 
in relation to other stages. The diagnostic odds ratio (DOR) was used to determine the lowest 
diagnostic score possible for the ‘MELmiR-7’ panel while still maintaining very high 
sensitivity and specificity. Moreover, upon comparison with currently used serological tests 
(LDH and S100B), we found that the ‘MELmiR-7’ panel was more sensitive than the 
combined power of both tests. Using the available data (Tubingen cohort), elevated levels of 
LDH and S100B were found in 40% (27/67) and 63% (42/67) of these patients (Table 2). In 
the same patients, the ‘MELmiR-7’ panel achieved 91% (63/67) (when ≥4 miRNAs reached 
or exceeded their optimal cut-points) sensitivity and ≥82% specificity (specificity could not 
be determined for serum LDH and S100B as ‘controls’ were not assayed). The sensitivity of 
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the ‘MELmiR-7’ panel was confirmed in an independent serial collection of stage IV patients 
(initial blood draw at lower disease burden and one at a higher disease burden) (Figure 2). 
Figure 2 highlights that the ‘MELmir-7’ panel can be used to monitor tumour progression in 
100% of the patients assessed (≥2 miRNAs with ≥1·5 fold relative expression). Subsequent 
AUROC analysis (Figure 2) highlights that if measured in isolation, the most informative 
markers would be miR-509-5p and miR-4731 (AUC=0·84 respectively). 
Members of the ‘MELmiR-17’ differentiate stage and are associated with survival in patient 
sera. 
To discern whether significant differences in stage could be found, we first assessed the 
‘MELmiR-17’ panel using Mann-Whitney tests (with corrected p values) combined with 
AUROC analysis for stage I/II vs. IV and stage III vs. IV. Table 3 summarizes the associated 
corrected p values and AUROC scores. Next, multivariate logistic regression was used to 
identify the minimum miRNAs required to predict differences in the melanoma stages which 
was illustrated using conditional inference trees (Supplementary Figures 9 and 10) and 
AUROC analysis (AUC scores for stage I/II vs. IV and stage III vs. IV were 0·989 and 
0·9945 respectively). There were no markers, however, that were significantly associated 
with time to recurrence when Cox regression was performed. 
The ‘MELmiR-17’ panel was next assessed to identify miRNAs related to OS in the serum 
cohorts from Tubingen (n=131) and Melanoma Institute of Australia (MIA; n=124) first 
separately and then jointly (n=255) (Table 2). The predictive performance of the joint model 
on each cohort was statistically equivalent to that of the best separate analysis on each cohort 
(likelihood ratio test; p=0·34 for MIA cohort; p=0·22 for Tubingen cohort), hence the joint 
model was used to analyse the combined Tubingen and MIA cohorts. Furthermore, the miR-
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4706 marker was dichotomized at Ct 37 to meet the proportionality assumption. The outcome 
from the combined analysis is summarised in Table 5. 
A conditional inference tree analysis for the survival data was then performed which showed 
that stage at blood draw together with miR-211 expression could be used to triage patients 
based on overall survival (OS) status (Figure 3 with Kaplan-Meier plots per each 
classification). Importantly, upon diagnosis with stage IV, miR-211 expression was able to 
discern survival based on high (Ct ≤24; median survival= 4·8 months, CI 4·5-5·9) and low 
expression (Ct ≥24·01; median survival= 2.7 yrs, CI 1·7-NA). 
Finally, the MELmiR-7 panel was further assessed for its utility in terms of predicting OS in 
serum cohorts having LDH and S100B status available (Tubingen) (Table 2). The ‘MELmiR-
7’ panel performed significantly better than both serum LDH and S100B (delta log likelihood 
= 11, p<0·001). 
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Discussion 
 Five-year survival proportions for melanoma are poor for patients with metastatic disease, 
however if disease is detected in its early stages, then survival is one of the highest for all 
cancers. Even for those with metastases, survival differs depending on the extent of disease 
spread. Patients with metastases confined to regional lymph nodes (stage III disease) have 5-
year survival of ~50%, whereas patients with widely disseminated metastases (stage IV 
disease) have 5-year survival of <15%. Thus better monitoring of a patient’s tumour burden 
may improve survival by precipitating earlier therapeutic interventions. In support of this, 
clinical trials in stage III unresectable and stage IV melanoma patients, treated with 
ipilimumab,
5
 vemurafenib,
4
 combined dabrafenib and trametinib
31
 or anti-PD1 
pembrolizumab,
32
  have observed improved overall survival  and response rate  in patients 
with lower disease volume (M1a/M1b) as compared to those with distal disease (M1c). 
Moreover, it is believed that there is potential for long-term survival if relapses are identified 
promptly with treatment initiated without delay.
33
 In clinical practice, there is currently a lack 
of reliable, sensitive and specific predictive biomarkers for detecting early melanoma 
progression.  This study aimed to identify a more effective biomarker that was sensitive and 
specific enough to identify early metastatic disease. Since commencement of this study there 
have been a number of studies investigating the utility of miRNAs to serve as melanoma 
blood and tissue biomarkers. 
19-21, 30, 34-36
 For example, a study by Friedman et al. 20 screened 
355 miRNAs in sera from 80 melanoma patients using a previously characterised panel of 
serum-expressed miRNAs. The authors found detectable expression for 170 miRNAs and a 
panel of five miRNAs (miR-150, miR-15b, miR-199a-5p, miR-33a, and miR-424) showed a 
significant association with recurrence-free survival. This five-miRNA signature was able to 
classify the patients into high and low recurrence risk. Our approach was to identify a panel 
of melanoma-related miRNAs that involved first screening a panel of melanoma cell lines 
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(n=55) in comparison with a group of other solid malignancies (cell lines were derived from 
breast, ovarian, colorectal, prostate, etc). 
22
 Interestingly, the five-miRNA panel indentified 
by Friedman et al. 
20
 was not present in our dataset which may indicate that this panel is not 
specifically melanoma-related but instead related to the tumourigenic process. We focused on 
miRNAs that were highly expressed or more predominantly expressed in melanoma with the 
premise that these may be both ‘diagnostic’ for melanoma and/or more easily detectable in 
patient serum. Our current approach differed from the aforementioned studies as: 1) this 
study harnessed the power of our previous comprehensive analysis of known miRNAs 
(n=1898) in relation to melanoma; 
22
 2) this study validated the cell-line derived miRNA 
panel (MELmiR-17) in a large of panel of stage III and IV melanoma tissues prior to serum 
analysis to confirm they were expressed; 3) this study used an ultra-sensitive method of 
detection (see Materials and Methods) to ensure that lowly expressed miRNAs could be 
detected. We have successfully used these approaches in a previous study where a panel of 
miRNAs were identified that was related to good and poor prognosis in stage III melanoma 
patients. 
21 However, our current study was limited by the lack of available serially 
collected specimens (to detect recurrence as in Friedman et al. 20) at time of study 
design.  To address this limitation, further studies in larger, independent, prospectively 
collected melanoma cohorts will be required to strengthen these data.  
In sum, we found that a ‘melanoma-related’ panel of miRNAs was expressed in metastatic 
melanoma in a stage-specific manner and, together with the tissue pathology and nodal status, 
was prognostic for recurrence and OS. These markers may therefore also be useful to support 
histopathologic diagnosis of metastatic deposits suspected of being melanoma. We further 
observed that expression of the various miRNAs from the MELmiR-17 panel in stage IV 
tissues was often lower than in stage III tissue, which is in keeping with previous studies. For 
example, miR-211 expression is commonly lost in subsets of melanoma cell lines,
22, 37
 and 
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miR-506, a member of the miR-506-514 cluster, has been shown to be lost during metastatic 
colonisation despite being up-regulated in early melanoma progression.
28, 38
 We have also 
recently reported that inhibition of miR-514a leads to increased cell proliferation.
22
 These 
data indicate that expression of this cluster reduces during melanoma progression. 
Currently there is an unmet need for a minimally invasive, highly specific, and predictive 
serum biomarker of melanoma burden. For many years the use of the seroprotein markers 
S100B and LDH has been disputed, due to reported inconsistencies in sensitivity and 
specificity.
6-10, 12-14
 Despite this lack of consensus, a recent study did find that elevated levels 
of S100B were prognostic of survival times in patients with unresectable melanoma.
39
 
Here, we present data that shows that our ‘MELmiR-7’ panel has the potential to be used as a 
primary screening tool for clinically undetected metastatic melanoma due to its high 
sensitivity (93%) and specificity (≥82%). However, detection of early melanoma lesions (in 
situ and stage I/II melanoma) is currently being adequately achieved (as evident by high 
survival rates) via clinical strategies. The ‘MELmiR-7’ panel could be utilized during routine 
follow-up (i.e. post primary excision of melanoma and later in advanced disease) of 
melanoma patients. In comparison with serum LDH and S100B, expression levels of the 
‘MELmiR-7’ panel performed better than both markers in predicting overall survival. We 
have shown that the ‘MELmir-7’ panel was measurable at time of progression in 100% of 
stage IV melanoma patients. These data suggest that this panel would therefore be suited to 
monitor tumour burden. Better monitoring of a patient’s tumour burden could improve 
survival by precipitating earlier therapeutic interventions. In support of this notion, clinical 
trials in stage III unresectable and stage IV melanoma patients, treated with ipilimumab,
5
 
vemurafenib,
4
 combined dabrafenib and trametinib
31
 or anti-PD1 pembrolizumab,
32
  have 
observed improved overall survival  and response rate  in patients with lower disease volume 
(M1a/M1b) as compared to those with distal disease (M1c). 
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According to the AJCC Staging committee, stage III melanoma patients have a 50% chance 
of survival beyond 5 years;
3
 these patients also remain the most difficult for whom to provide 
effective treatments/surveillance regimens and accurate survival estimates. Following 
treatment, stage III patients are subjected to a series of physical examinations, scans and 
serology at regular intervals. The frequency of these tests is deemed necessary for early 
detection of recurrence; however this causes a burden to both the patient and the healthcare 
system. It is important to note that these guidelines are not universally accepted and differ 
from centre to centre.
15
 We foresee that the ‘MELmiR-7’ panel could be offered to patients to 
complement physical examination. If the diagnostic score for melanoma positivity has 
changed from earlier measurements, then this may indicate the presence of disease recurrence 
and as such, these patients may qualify earlier for adjuvant, systemic, or targeted therapies 
that would otherwise be only offered to stage IV patients. As previously discussed, due to the 
panel’s high sensitivity and specificity, the use of this miRNA panel in this manner has the 
potential to increase the chances of survival, by earlier and more precise detection of the 
presence of metastases. 
In terms of prognosis, elevated miR-211 expression levels were associated with poorer 
survival in stage IV patients. Therefore, miR-211 measurement might allow better triaging of 
patients diagnosed with stage IV disease, into good and poor prognosis which would be 
highly informative for not only the treating clinician but also for the quality of life of the 
patients.  
The original premise of this study was that the melanoma-enriched miRNAs identified in our 
previous study 
22
 would be translated directly to the expression observed in melanoma 
patient-derived serum. Evidence for this notion is apparent in the serially collected stage IV 
melanoma patients, when, at progression (or recurrence), the MELmiR-7 panel increases, 
which is reflective of increased tumour burden (i.e. the detectable miRNA expression was 
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from the presence of tumour cells and/or tumour derived extracellular vesicles (e.g. 
exosomes) in the circulation). These data strongly suggest that the expression is tumour 
derived and as such this panel could be considered melanoma-related. However, as we have 
noted, we observe a paradoxical decrease in the expression of the significantly expressed 
(mir-509-5p, miR-509-3p, mir-4731-5p, miR4487, miR4706) miRNAs when melanoma 
serum cohorts were compared with control cohorts. These data thus provide evidence that the 
assessed miRNAs (detectable in serum) are not restricted to the melanocytic lineage as 
initially thought. The source of this miRNA expression is currently unknown but could 
include cells of the haematopoietic lineage including T-cells, B-cells or NK cells. This loss of 
expression from a ‘non-tumour’ source has not been elucidated but warrants further 
investigation. An observed loss of expression of serum-derived miRNAs has been noted 
previously by Friedman et al. 
20
 in post-operative specimens as compared to specimens 
collected at disease relapse. A plausible reason for a loss of expression observed in the serum 
may be due to a cytokine-driven systemic response. For example, pro-inflammatory 
cytokines have been shown to down-regulate miRNAs present in the circulation. 
40
 
Specifically, in a study by Hooten et al., 
40
 the serum expression of miR-181a was found to 
be negatively correlated with pro-inflammatory cytokines IL-6 and TNFα and positively 
correlated with the anti-inflammatory cytokines TGFβ and IL-10. 40 Recently, it has been 
confirmed that IL-6 expression is induced in melanoma cells with mutant BRAF (V600E). 
Therefore a possible explanation for what we have observed is that the miRNAs of interest 
could be expressed by non-melanocyte derived cells where expression is down-regulated in 
patients with melanoma due to melanoma-related cytokines (e.g. IL-6). 
41
 
In conclusion, we envisage that as a growing number of miRNA-panels have been identified 
as potential prognostic indicators for melanoma, 
19-21
 it will eminently feasible to quantify 
circulating cell-free miRNAs directly,
42
 paving the way for rapid measurements to occur in a 
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diagnostic laboratory. Given these advances, combined with the data presented herein, future 
melanoma treatment regimens should consider the utility of miRNAs as a prognostic aid in 
the clinical setting. Our sensitive and specific miRNA panel, in combination with newly 
identified panels, may enable more precise measurement of disease progression, and in 
conjunction with current therapy options, may herald an increase in overall survival. 
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TABLE LEGENDS 
Table 1 
Descriptive statistics of all tissue cohorts used within the study. 
Table 2 
Descriptive statistics of all serum cohorts used within the study. Bolded texts are the cohorts 
that were used in the analysis. 
Table 3 
Table provides a summary of the Mann-Whitney tests and AUROC analyses that were 
performed in each cohort for 13 detectable miRNAs in serum derived from melanoma 
patients and controls. P values were corrected for false discovery rate (FDR) via the 
Benjamini–Hochberg (BH) procedure. ns = non-significant. Shading represents the 
MELmiR-7 panel. Brackets represent the 95% Confidence Interval (CI). 
Table 4 
Summaries of the diagnostic test statistics generated when AJCC staged melanoma is 
compared with controls. 
Table 5 
Summarizes the output from a multivariate survival analysis of serum miRNAs. A total of 
seven miRNAs contributed to overall survival with five reaching statistical significance 
(p<0.05). Stage at diagnosis was included in the analysis. HR = Hazard ratio. ns = non-
significant. CI = confidence interval. 
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FIGURE LEGENDS 
Figure 1 
Melanoma-related miRNAs were first identified in a ‘Discovery set’ of 233 miRNAs 
previously found to be significantly associated with melanoma.
22
  The 18-miRNA panel was 
measured firstly in an independent cohort of FFPE melanoma tissues (Tissue validation 
cohort; see Materials and Methods). The miRNA panel was then measured in cohorts of 
serum derived from controls in comparison to AJCC staged melanoma patients (stages I-IV) 
(Serum Validation Cohorts; see Materials and Methods). The detectable miRNAs (listed) 
were carried forward for further statistical comparisons. 
Figure 2 
Serially collected blood samples from stage IV melanoma patients highlight the utility of the 
MELmiR-7 panel as a whole in monitoring tumour progression. AUC scores were 
determined via an AUROC analysis. Coloured bars represent relative fold change of 
progression sample in relation to the initial blood draw. 
Figure 3 
A conditional inference tree (CI tree) illustrates that stage at blood draw together with miR-
211 expression can triage patients based on known survival outcomes when melanoma was 
the confirmed cause of death. miR-211 expression cutpoints were determined by the CI 
analysis. Ct values ≤24 (or high expression) and ≥24.01 (or low expression) allowed for a 
significant splitting of the stage IV patients into good and poor prognosis patients. P values as 
indicated. Solid lines in the Kaplan Meier survival curves represent the observed events. 
Dotted lines are the 95% Confidence Intervals. n = number of patients in each group. 
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Table 1 Descriptive Statistics for tissue cohorts 
Prognostic 
factors 
 
PAH Cohort 
n (%) 
MIA Cohort 
n (%) 
MIA Cohort 
n (%) 
 Totals 66 (100) 10 (100) 10 (100) 
Stage at 
collection 
III 
IV 
66 (100) 
- 
10 (100) 
- 
- 
10 (100) 
Stage 
subclass 
IIIB 
IIIC 
Unknown 
25 (38) 
41(62) 
0 (0) 
- 
- 
0 (0) 
- 
- 
- 
Sex 
Male 
Female 
35 (53) 
31 (47) 
7 (70) 
3 (30) 
5 (50) 
5 (50) 
Age at 
tissue 
collection 
20-30 
31-40 
41-50 
51-60 
61+ 
Unknown 
6 (9) 
9 (14) 
15 (23) 
11 (17) 
28 (42) 
0 (0) 
- 
- 
- 
- 
- 
10 (100) 
1 (10) 
0 (0) 
0 (0) 
2 (20) 
7 (70) 
0 (0) 
Histological 
subtype of 
primary 
 
SSM 
Nodular 
LMM 
DM 
Unknown 
35 (53) 
14 (21) 
1 (2) 
1 (2) 
15 (23) 
- 
- 
- 
- 
10 (100) 
- 
- 
- 
- 
10 (100) 
N-stage 
1 
2 
3 
Unknown 
34 (52) 
7 (11) 
25 (38) 
0 (0) 
- 
- 
- 
10 (100) 
- 
- 
- 
10 (100) 
Recurrence 
at Last FU 
Yes 
No 
Unknown 
45 (68 
21(32) 
0 (0) 
- 
- 
10 (100) 
- 
- 
10 (100) 
Cause of 
death 
Alive 
Melanoma 
Other Ca. 
Not Ca. 
Unknown 
Missing 
data 
24 (36) 
42 (64) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
- 
- 
- 
- 
- 
10 (100) 
- 
- 
- 
- 
- 
10 (100) 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
36 
 
Table 2- Descriptive Statistics for serum cohorts 
Prognostic 
factors 
 
 
 
Healthy 
Controls 
n (%) 
 
High 
Nevus 
Count 
n (%) 
 
History 
of 
Melanoma 
n (%) 
Tubingen 
Cohort 
Stage 
I/II 
n (%) 
MIA 
Cohort 
Stage 
I/II 
n (%) 
 
Combined 
Stage 
I/II 
n (%) 
MIA 
Cohort 
Stage 
III 
n (%) 
Tubingen 
Cohort 
Stage 
IV 
n (%) 
MIA 
Cohort 
Stage 
IV 
n (%) 
 
Combined 
Stage 
IV 
n (%) 
 Totals 102 (100) 12 (100) 16 (100) 52 (100) 34 (100) 86 (100) 50 (100) 79 (100) 40 (100) 119 (100) 
Sex Male 
Female 
50 (49) 
52 (51) 
2 (17) 
10 (83) 
7 (44) 
9 (56) 
19 (37) 
33 (63) 
20 (59) 
14 (41) 
39 (45) 
47 (55) 
32 (64) 
18 (36) 
48 (61) 
31 (39) 
28 (70) 
12 (30) 
76 (64) 
43 (36) 
Age at 
blood 
draw 
20-30 
31-40 
41-50 
51-60 
61+ 
4 (4) 
5 (5) 
28 (27) 
19 (19) 
46 (45) 
8 (67) 
4 (33) 
- 
- 
- 
1 (6) 
- 
2 (13) 
6 (38) 
7 (44) 
3 (6) 
2 (4) 
12 (23) 
10 (19) 
25 (48) 
3 (9) 
2 (6) 
2 (6) 
10 (29) 
17 (50) 
6 (7) 
4 (5) 
14 (16) 
20 (23) 
42 (49) 
2 (4) 
3 (6) 
6 (12) 
15 (30) 
24 (48) 
3 (4) 
3 (4) 
19 (24) 
19 (24) 
35 (44) 
1 (2) 
- 
5 (12) 
9 (23) 
25 (63) 
4 (3) 
3 (3) 
24 (20) 
28 (24) 
60 (50) 
Histological 
subtype of 
primary 
 
SSM 
Nodular 
LMM 
ALM 
Unknown 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
16 (100) 
19 (36) 
14 (27) 
4 (8) 
2 (4) 
13 (25) 
- 
- 
- 
- 
34 (100) 
19 (22) 
14 (16) 
4 (5) 
2 (2) 
47 (55) 
- 
- 
- 
- 
50 (100) 
34 (43) 
18 (23) 
- 
6 (7) 
21 (27) 
- 
- 
- 
- 
40 (100) 
34 (29) 
18 (15) 
- 
6 (5) 
61 (51) 
Breslow’s 
thickness of  
≤1 mm 
1.01-2 mm 
- 
- 
- 
- 
- 3 (6) - 3 (3) - 18 (23) - 18 (15) 
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primary 2.01-4 mm 
>4 mm 
Unknown 
- 
- 
- 
- 
- 
- 
- 
- 
- 
16 (100) 
32 (61) 
11 (21) 
5 (10) 
1 (2) 
- 
- 
- 
34 (100) 
32 (37) 
11 (13) 
5 (6) 
35 (41) 
- 
- 
- 
50 (100) 
12 (15) 
20 (25) 
16 (20) 
13 (16) 
- 
- 
- 
40 (100) 
12 (10) 
20 (17) 
16 (13) 
43 (36) 
M staging M1a 
M1b 
M1c 
Unknown 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
19 (24) 
16 (20) 
44 (56) 
- 
15 (38) 
9 (18) 
16 (28) 
- 
34 (29) 
25 (21) 
60 (50) 
Serum LDH Elevated 
Normal 
Unknown 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
27 (34) 
42 (53) 
10 (13) 
7 (18) 
5 (12) 
28 (70) 
34 (29) 
47 (40) 
38 (32) 
S100B Elevated 
Normal 
Unknown 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
   43 (54) 
25 (32) 
11 (14) 
- 
- 
40 (100) 
45 (38) 
25 (21) 
55 (46) 
Cause of 
Death 
Alive 
Melanoma 
Other Ca. 
Not Ca. 
Unknown 
Missing 
data 
- 
- 
- 
- 
- 
102 
12 (100) 
- 
- 
- 
- 
- 
16 (100) 
- 
- 
- 
- 
- 
48 (92) 
2 (4) 
1 (2) 
- 
1 (2) 
- 
30 (88) 
4 (12) 
- 
- 
- 
- 
78 (91) 
6 (7) 
1 (1) 
- 
1 (1) 
- 
32 (64) 
15 (30) 
- 
- 
3 (6) 
- 
15 (19) 
62 (78) 
1 (1) 
- 
1 (1) 
 
20 (50) 
20 (50) 
- 
- 
- 
35 (29) 
82 (69) 
1 (1) 
- 
1 (1) 
Bolded texts are the cohorts that were used in the analysis 
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Table 3 Univariate analysis in serum cohorts for detectable miRNA 
Comparison Test 
miR-
145 
miR-
146a 
miR-16 
miR-
204 
miR-211 
miR-
363-3p 
miR-
4487 
miR-
4706 
miR-
4731 
miR-
506-
3p 
miR-
509-3p 
miR-
509-5p 
miR-
514a 
Controls 
(n=130) 
vs. Stage 
I/II (n=86) 
 
Mann-
Whitney 
U test 
0·026 <0·0001 <0·0001 ns ns 0·0088 <0·0001 <0·0001 <0·0001 ns <0·0001 ns ns 
AUROC 
score 
0·64 
(0·56, 
0·7) 
0·73 
(0·67, 
0·80) 
0·85 
(0·79, 
0·90) 
0·59 
(0·48, 
0·67) 
0·53 
(0·47, 
0·59) 
0·66 
(0·58, 
0·72) 
0·95 
(0·91, 
0·98) 
0·88 
(0·83, 
0·93) 
0·89 
(0·85, 
0·94) 
0·53 
(0·48, 
0·59) 
0·76 
(0·69, 
0·82) 
0·95 
(0·92, 
0·98) 
0·53 
(0·47, 
0·59) 
Controls 
(n=130) 
vs. Stage 
III (n=50) 
 
Mann-
Whitney 
U test 
ns 0·039 <0·0001 ns ns ns <0·0001 <0·0001 <0·0001 ns <0·0001 <0·0001 ns 
AUROC 
score 
0·57 
(0·48, 
0·66) 
0·65 
(0·57, 
0·73) 
0·87 
(0·81, 
0·91) 
0·54 
(0·46, 
0·62) 
0·55 
(0·46, 
0·65) 
0·62 
(0·49, 
0·70) 
0·93 
(0·87, 
0·98) 
0·85 
(0·79, 
0·91) 
0·85 
(0·78, 
0·90) 
0·54 
(0·47, 
0·62) 
0·72 
(0·64, 
0·79) 
0·93 
(0·89, 
0·96) 
0·53 
(0·48, 
0·61) 
Controls 
(n=130) 
vs. Stage 
IV 
(n=119) 
 
Mann-
Whitney 
U test 
ns ns 0·0001 0·008 <0·0001 ns <0·0001 <0·0001 <0·0001 ns <0·0001 <0·0001 ns 
AUROC 
score 
0·53  
(0·47, 
0·59) 
0·60 
(0·53, 
0·66) 
0·70 
(0·64, 
0·77) 
0·65 
(0·57, 
0·71) 
0·72 
(0·65, 
0·78) 
0·55 
(0·48, 
0·61) 
0·89 
(0·84, 
0·93) 
0·85 
(0·80, 
0·90) 
0·93 
(0·89, 
0·96) 
0·53 
(0·47, 
0·59) 
0·74 
(0·67, 
0·80) 
0·91 
(0·87, 
0·94) 
0·57 
(0·47, 
0·64) 
Stage III 
(n=50) vs. 
Stage IV 
Mann-
Whitney 
U test 
ns ns ns 0·025 0·025 0·025 0·0099 ns 0·025 ns <0·0001 ns ns 
AUROC 
score 
0·55 
(0·47, 
0·64) 
0·54 
(0·47, 
0·61) 
0·64 
(0·55, 
0·72) 
0·67 
(0·59, 
0·75) 
0·66 
(0·58, 
0·74) 
0·66 
(0·58, 
0·74) 
0·73 
(0·62, 
0·82) 
0·54 
(0·47, 
0·62) 
0·67 
(0·58, 
0·76) 
0·55 
(0·47, 
0·63) 
0·78 
(0·71, 
0·84) 
0·53 
(0·47, 
0·61) 
0·57 
(0·46, 
0·66) 
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(n=119) 
 
Stage I/II 
(n=86) vs. 
Stage IV 
(n=119) 
 
Mann-
Whitney 
U test 
0·026 0·043 0·031 0·0002 0·0014 0·0029 0·0082 ns ns ns <0·0001 ns ns 
AUROC 
score 
0·64 
(0·58, 
0·72) 
0·62 
(0·55, 
0·70) 
0·63 
(0·56, 
0·70) 
0·72 
(0·66, 
0·79) 
0·71 
(0·65, 
0·78) 
0·68 
(0·61, 
0·75) 
0·67 
(0·59, 
0·74) 
0·58 
(0·49, 
0·66) 
0·57 
(0·48, 
0·65) 
0·51 
(0·48, 
0·59) 
0·79 
(0·73, 
0·86) 
0·56 
(0·44, 
0·65) 
0·58 
(0·47, 
0·66) 
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Table 4 Sensitivity and Specificity summary 
MELmiR-7-
panel 
Melanoma vs. 
Controls 
Stage I/II vs. 
Controls 
Stage III vs. 
Controls 
Stage IV vs. 
Controls 
Diagnostic Score ≥4 ≥4 ≥4 ≥4 
Sensitivity 93% 93% 86% 95% 
Specificity ≥82% ≥82% ≥82% ≥82% 
False Positive 
Rate 
18% 18% 18% 18% 
False Negative 
Rate 
7% 7% 14% 5% 
Positive 
Predictive Value 
(PPV) 
91% 77% 64% 82% 
Negative 
Predictive Value 
(PPV) 
85% 95% 94% 95% 
Likelihood Ratio 
Positive 
5·01 5·04 4·66 5·14 
Likelihood Ratio 
Negative 
0·09 0·09 0·17 0·06 
Diagnostic Odds 
Ratio (DOR) 
54·86 58·89 27·13 83·18 
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Table 5 Multivariate survival analysis of serum miRNAs and melanoma stage 
Covariate HR 
Lower 
95%CI 
Upper 
95%CI 
p Value 
Stage III 6·03 2·33 15·56 0·0002 
Stage IV 8·48 3·12 23·01 <0·0001 
hsa-miR-16 1·04 0·88 1·23 ns 
hsa-miR-211 0·87 0·82 0·91 <0·0001 
hsa-miR-4487 0·88 0·79 0·98 0·02 
hsa-miR-4706 0·45 0·29 0·69 0·0002 
hsa-miR-4731 0·98 0·90 1·06 ns 
hsa-miR-509-3p 1·04 1·00 1·09 ns 
hsa-miR-514a 0·92 0·85 0·99 0·02 
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FIGURES: 
Figure 1 Study summary 
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Figure 2 Expression of MELmiR-7 in stage IV progression patients 
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Figure 3 Conditional Inference tree predicting survival outcomes 
 
